Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The "Big 3 Stack" for hair loss treatment, which includes Minoxidil for hair density improvement, Ketoconazole shampoo for enhancing hair volume and thickness, and Finasteride for blocking hair loss causing hormones. Microneedling can boost Minoxidil's effects.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.

A user shared their experience with hair loss treatments, using minoxidil, pyrilutamide, alfatrodial, and nizoral to improve hair density and thickness. They reported positive results without side effects and emphasized the importance of consistency with topical treatments.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.

Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.

A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.

Dutasteride is more effective than finasteride for hair loss as it blocks more of the enzyme causing hair loss. New treatments like stem cell therapies and alternatives to minoxidil are being explored, but major advancements are still years away.

There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.